Literature DB >> 7501149

Primary lateral sclerosis: a neuropsychological study.

R J Caselli1, B E Smith, D Osborne.   

Abstract

Nine patients with clinically diagnosed, radiologically supported primary lateral sclerosis underwent cognitive testing. None was demented, but eight had mild cognitive impairment. Performances were most consistently impaired on neuropsychological tests sensitive to frontal lobe functions, followed by tests sensitive to memory. Cognitive testing may be useful in helping to establish a cortical localization in patients with the syndrome of progressive spasticity. There are potential nosologic relations between primary lateral sclerosis and other degenerative frontal lobe syndromes, such as frontal lobe dementia and progressive spasticity with dementia.

Entities:  

Mesh:

Year:  1995        PMID: 7501149     DOI: 10.1212/wnl.45.11.2005

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

1.  Intrathecal baclofen for spasticity in primary lateral sclerosis.

Authors:  Jerônimo Buzetti Milano; Mauricio Coelho Neto; Sonival Cândido Hunhevicz; Walter Oleschko Arruda; Ricardo Ramina; Erasmo Barros
Journal:  J Neurol       Date:  2005-03-29       Impact factor: 4.849

2.  Extra-motor cerebral changes and manifestations in primary lateral sclerosis.

Authors:  Eoin Finegan; Stacey Li Hi Shing; Rangariroyashe H Chipika; Kai Ming Chang; Mary Clare McKenna; Mark A Doherty; Jennifer C Hengeveld; Alice Vajda; Niall Pender; Colette Donaghy; Siobhan Hutchinson; Russell L McLaughlin; Orla Hardiman; Peter Bede
Journal:  Brain Imaging Behav       Date:  2021-01-07       Impact factor: 3.978

Review 3.  Primary Lateral Sclerosis.

Authors:  Jeffrey M Statland; Richard J Barohn; Mazen M Dimachkie; Mary Kay Floeter; Hiroshi Mitsumoto
Journal:  Neurol Clin       Date:  2015-09-08       Impact factor: 3.806

4.  Primary lateral sclerosis as progressive supranuclear palsy: diagnosis by diffusion tensor imaging.

Authors:  Elizabeth A Coon; Jennifer L Whitwell; Clifford R Jack; Keith A Josephs
Journal:  Mov Disord       Date:  2012-04-19       Impact factor: 10.338

5.  A pilot study of the prevalence of psychiatric disorders in PLS and ALS.

Authors:  Edward D Huey; Jeremy Koppel; Nicole Armstrong; Jordan Grafman; Mary Kay Floeter
Journal:  Amyotroph Lateral Scler       Date:  2010-05-03

6.  Primary lateral sclerosis: clinical, neurophysiological, and magnetic resonance findings.

Authors:  J Kuipers-Upmeijer; A E de Jager; J M Hew; J W Snoek; T W van Weerden
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-11       Impact factor: 10.154

7.  Self-Regulation and Executive Functioning as Related to Survival in Motor Neuron Disease: Preliminary Findings.

Authors:  Natasha E Garcia-Willingham; Abbey R Roach; Edward J Kasarskis; Suzanne C Segerstrom
Journal:  Psychosom Med       Date:  2018-09       Impact factor: 4.312

8.  Intrahemispheric and interhemispheric structural network abnormalities in PLS and ALS.

Authors:  Federica Agosta; Sebastiano Galantucci; Nilo Riva; Adriano Chiò; Stefano Messina; Sandro Iannaccone; Andrea Calvo; Vincenzo Silani; Massimiliano Copetti; Andrea Falini; Giancarlo Comi; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2013-04-30       Impact factor: 5.038

9.  Primary lateral sclerosis and the amyotrophic lateral sclerosis-frontotemporal dementia spectrum.

Authors:  Smriti Agarwal; Elizabeth Highton-Williamson; Jashelle Caga; José M Matamala; Thanuja Dharmadasa; James Howells; Margaret C Zoing; Kazumoto Shibuya; Nimeshan Geevasinga; Steve Vucic; John R Hodges; Rebekah M Ahmed; Matthew C Kiernan
Journal:  J Neurol       Date:  2018-06-04       Impact factor: 4.849

10.  Eye-tracking in amyotrophic lateral sclerosis: A longitudinal study of saccadic and cognitive tasks.

Authors:  Malcolm Proudfoot; Ricarda A L Menke; Rakesh Sharma; Claire M Berna; Stephen L Hicks; Christopher Kennard; Kevin Talbot; Martin R Turner
Journal:  Amyotroph Lateral Scler Frontotemporal Degener       Date:  2015-08-27       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.